NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Zealand, Palestinian The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Nutrition A cookie is a small text file that a web server stores in browser software. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Innovation, Bayer The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . The investment portfolio includes more than 50 companies. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Bayer, Research and Africa, Sri Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Management, Bayer 2021 Feb;9(2):156-169. of 24. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. ////// Science for a better We will retain your Personal Data as may be required or permitted by applicable law. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). securities in any Relevant Member State means the communication in any form and by any means of Safety, Climate Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. An investment decision regarding the securities referred to herein should only Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. permitted to view these materials, please exit this webpage. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Join to view profile NextPoint Therapeutics, Inc. . good faith and for information purposes only. 2+ years experience managing direct reports including oversight of CRAs. Sports, Promotion Prospectus Directive. Information, Recognizing Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Furthermore, where permissible, we may charge for this service. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. to proceed to electronic versions of these materials. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. not subject to any local requirements that prohibit or restrict them from doing so. access to the materials is prohibited or restricted. Drs. Headquarters, Dominican transaction not subject to, the registration requirements of the Securities Act. & They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). We do not accept any responsibility or liability for these policies and procedures. Any person who is not a relevant person should not act or rely on the Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Leaps by Bayer, Bayer AG's impact investment arm,. The financing will be used to advance NextPoint . Strategy, Bio Revolution NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. About NextPoint Therapeutics. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Publications, Job Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Position, Position Trends, Growing NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Potential, Leading http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. By clicking on the I AGREE button, I confirm that I am permitted in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. person to whom it is unlawful to make such offer or solicitation. To exercise your rights, you may contact us as at. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Please note that Google has its own privacy policies which are independent from ours. +49 30 468 1111, Alfred-Nobel-Str. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. And here is our regular feature in which we highlight a different person each week. Member State, except that an offer to the public in such Relevant Member State of any securities may Authority, United Arab Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Proc Natl Acad Sci U S A. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), of We use technical and organizational security measures designed to secure and protect Personal Data. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses.